The Challenge of PSC Clinical Trials: When “Success” No Longer Simply Means Waiting for Liver Failure

For rare hepatobiliary diseases with variable progression, clinical trials are often constrained by a practical reality: the outcomes that truly matter may take many years to occur. Primary sclerosing cholangitis (PSC) is exactly this kind of disease. It causes repeated inflammation, narrowing, and fibrosis of the bile ducts, and some patients ultimately progress to cirrhosis, liver failure, or liver transplantation, but the pace of the disease varies greatly from person to person.

Fierce Biotech recently addressed the evolution of clinical trial endpoints in PSC, noting that the field is rethinking how “success” should be measured. Because the publicly available summary is currently quite limited, the specific companies, drugs, or regulatory details mentioned in the article cannot be confirmed; but the issue indicated by the headline is indeed a core bottleneck that PSC research and development has long faced.

In clinical research, the most persuasive endpoints are usually hard clinical outcomes such as death, liver transplantation, and hepatic decompensation. The problem is that if every trial must wait until enough of these events have accumulated, study timelines may become excessively long, and patient recruitment may become extremely difficult. For PSC, where the patient population is limited and disease course is highly heterogeneous, this is not merely a statistical problem; it determines whether a candidate therapy has a fair chance to be evaluated.

As a result, researchers and pharmaceutical companies in recent years have placed greater emphasis on surrogate or intermediate measures that can be observed earlier, such as alkaline phosphatase (ALP), bilirubin, liver fibrosis assessment, imaging changes, and patient-reported outcomes such as itching and fatigue. The appeal of these measures is that they can reflect biological changes more quickly; but they also raise another question: does an improvement in the numbers truly predict long-term clinical benefit? If the answer is not robust enough, a trial may appear successful without necessarily meaning that the patient’s future has been changed.

The difficulty with PSC also lies in the fact that the disease itself is not straightforward. It often coexists with inflammatory bowel disease, the location and severity of bile duct damage vary, and patients also face risks such as cholangiocarcinoma. A single biochemical value can hardly capture all of these dimensions; imaging and noninvasive fibrosis tools may come closer to reflecting organ-level changes, but they require standardized interpretation, validation, and comparability across trials.

**Background Context**

This debate over endpoints is not merely a technical detail, but a microcosm of drug development for rare diseases. Regulators are generally willing to consider more flexible trial designs, especially in areas with high unmet medical need; but flexibility does not mean lowering the evidentiary threshold. For PSC, the more reasonable direction may not be to search for one perfect measure, but to assemble biochemistry, imaging, symptoms, and long-term follow-up into a more credible chain of evidence.

The information currently available publicly is insufficient to determine whether the “endpoint evolution” described by Fierce Biotech is linked to a specific new trial or regulatory development. What is certain is that for PSC drug development to move forward, it must answer a question stricter than any efficacy slogan: whether improvement in early endpoints can reliably represent less bile duct injury, fewer complications, and the postponement or avoidance of liver transplantation for patients. That answer will determine how future clinical trials are designed, and it will also determine when patients can see treatment options that are truly meaningful.